Private Manufacturers' Thresholds to Invest in Comparative Effectiveness Trials

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.30, Iss.10, 2012-10, pp. : 859-868

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives and their Implications for Prioritizing Public Investments in Comparative Effectiveness Research

By Meltzer David

PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. : 843-853

Adis International

Access to resources Recommend Favorite

Prioritizing Comparative Effectiveness Research: Are Drug and Implementation Trials Equally Worth Funding?

By Gandjour Afschin

PharmacoEconomics, Vol. 29, Iss. 7, 2011-07 ,pp. : 555-561

Adis International

Access to resources Recommend Favorite

Comparative Effectiveness Without Head-to-Head Trials: A Method for Matching-Adjusted Indirect Comparisons Applied to Psoriasis Treatment with Adalimumab or Etanercept

By Signorovitch James E.

PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. : 935-945

Adis International

Access to resources Recommend Favorite

Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials

By Mullins C. Daniel Whicher Danielle

PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. : 969-976

Adis International

Access to resources Recommend Favorite

Comparative Effectiveness of Atypical Antipsychotics in Schizophrenia: What have Real-World Trials Taught Us?

By Attard Azizah Taylor David M.

CNS Drugs, Vol. 26, Iss. 6, 2012-06 ,pp. : 491-508

Adis International

Access to resources Recommend Favorite